Lerdelimumab

Drug Profile

Lerdelimumab

Alternative Names: 6B1; Anti-TGF-beta-2 monoclonal antibody - Cambridge Antibody Technology; Anti-transforming-growth-factor-beta-2 monoclonal antibody - Cambridge Antibody Technology; CAT 152; Human anti-TGF-beta-2 monoclonal antibody - Cambridge Antibody Technology; TGF-beta-2 monoclonal antibody - Cambridge Antibody Technology; Trabio

Latest Information Update: 22 Dec 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Cambridge Antibody Technology
  • Class Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Transforming growth factor beta2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Cataracts; Proliferative vitreoretinopathy; Scars

Most Recent Events

  • 27 Jun 2005 Discontinued - Phase-II for Proliferative vitreoretinopathy in United Kingdom (unspecified route)
  • 27 Jun 2005 Discontinued - Preclinical for Cataracts (unspecified route)
  • 23 Mar 2005 Discontinued - Phase-II/III for Scars prevention in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top